US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

ESG Concept

2,762.60

-52.2859-1.86%

Number of Gainers:7

Number of Losers:36

Number of Flat:1

PE:- -

High:2,815.18

Open:2,815.18

Low:2,754.91

Close:2,814.88

Loading ...

BRIEF-Vertex Announces UK Mhra Approval Of Alyftrek

Why Comfort Systems USA Stock Slid 17% Last Month

BlackRock, Inc. (BLK): Jim Cramer Says, ‘It’s Worth Much More Than It’s Selling For!’

Vertex Pharmaceuticals Gets UK Regulatory Approval for Alyftrek to Treat Cystic Fibrosis

MT Newswires Live

FactSet Research Is Maintained at Equal-Weight by Wells Fargo

BUZZ-Deutsche Bank initiates coverage on some US trucking firms

Vertex Pharmaceuticals announces MHRA approval of ALYFTREK for CF

Vertex Pharmaceuticals Inc - Working With Nice and Nhs for Alyftrek Access

THOMSON REUTERS

Vertex Announces UK Mhra Approval of Alyftrek® (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class Cftr Modulator for the Treatment of Cystic Fibrosis

THOMSON REUTERS

Do Its Financials Have Any Role To Play In Driving Fastenal Company's (NASDAQ:FAST) Stock Up Recently?

Simply Wall St.

THE MEXICO FUND, INC. DECLARES DISTRIBUTION

COTY Stock Plunges More Than 25% in 3 Months: What Should You Do?

Is the Options Market Predicting a Spike in Applied Materials (AMAT) Stock?

Is it Worth Adding ResMed Stock to Your Portfolio Now?

InflaRx Showcases Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

Vertex Pharmaceuticals' Triple Combination Cystic Fibrosis Therapy Alyftrek Receives Approval in UK

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.tigerhkgo.com/stock/BK4567/news?page=30"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK4567"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4567\",,,,,undefined,":{"symbol":"BK4567","market":"US","secType":"PLATE","nameCN":"ESG Concept","latestPrice":2762.5964,"timestamp":1742327999999,"preClose":2814.8823,"halted":0,"volume":407327131,"delay":0,"changeRate":-0.018575,"change":-52.285889,"pbRate":10.798689,"amount":58168127122.173904,"amplitude":0.021411,"prevYearClose":3061.5488,"fiveDayClose":2707.2715,"twentyDayClose":3083.5647,"turnoverRate":0.009024,"marketCap":8556414600456,"floatMarketCap":8411720661120,"peRate":32.648013},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4567\",,,,,undefined,":{"symbol":"BK4567","high":2815.1843,"amplitude":0.021411,"preClose":2814.8823,"low":2754.9143,"pbRate":"10.798689","latestPrice":2762.5964,"volume":407327131,"delay":0,"open":2815.1843,"prevYearClose":3061.5488,"prevWeekClose":2820.2246,"prevMonthClose":2921.397,"prevQuarterClose":3061.5488,"fiveDayClose":2707.2715,"twentyDayClose":3083.5647,"sixtyDayClose":3149.8818,"secType":"PLATE","market":"US","turnoverRate":0.009024,"peRate":32.648013,"marketCap":8556414600456,"floatMarketCap":8411720661120,"timestamp":1742327999999,"nameCN":"ESG Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4567\",,,,undefined,":{"bkCode":"BK4567","up":7,"down":36,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4567\",pageSize:16,pageCount:30,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2517349458","title":"BRIEF-Vertex Announces UK Mhra Approval Of Alyftrek","url":"https://stock-news.laohu8.com/highlight/detail?id=2517349458","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517349458?lang=en_us&edition=fundamental","pubTime":"2025-03-08 00:32","pubTimestamp":1741365173,"startTime":"0","endTime":"0","summary":"BRIEF-Vertex Announces UK Mhra Approval Of AlyftrekMarch 7 (Reuters) - Vertex Pharmaceuticals Inc VRTX.O:VERTEX ANNOUNCES UK MHRA APPROVAL OF ALYFTREK (DEUTIVACAFTOR/TEZACAFTOR/VANZACAFTOR), A ONCE-DA","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250307:nTUA7VCKSK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2456880835.USD","BK4567","IE00BZ9MQY76.HKD","BK4588","LU2417539215.USD","IE0002141913.USD","IE00BJJMRZ35.SGD","LU0289739699.SGD","LU2237438978.USD","BK4533","LU0417517546.SGD","IE00B4R5TH58.HKD","IE0002270589.USD","LU0823416689.USD","IE0009355771.USD","IE00B19Z9Z06.USD","LU2236285917.USD","LU1035775433.USD","LU1430594728.SGD","BK4139","LU1069344957.HKD","LU1093756168.USD","LU1585245621.USD","LU2362541273.HKD","LU0061475181.USD","LU2362540622.SGD","IE00BJT1NW94.SGD","LU2324357040.USD","IE00B19Z9P08.USD","LU2362541513.USD","IE00B19Z3B42.SGD","LU2462157665.USD","LU0320765992.SGD","LU0234570918.USD","LU0256863811.USD","LU0889565916.HKD","IE00BFTCPJ56.SGD","LU0058720904.USD","VRTX","IE00B19Z3581.USD","IE00B894F039.SGD","LU0079474960.USD","LU1093756325.SGD","BK4532","BK4585","IE00B2B36J28.USD","LU0109394709.USD"],"gpt_icon":0},{"id":"2517456811","title":"Why Comfort Systems USA Stock Slid 17% Last Month","url":"https://stock-news.laohu8.com/highlight/detail?id=2517456811","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517456811?lang=en_us&edition=fundamental","pubTime":"2025-03-08 00:12","pubTimestamp":1741363920,"startTime":"0","endTime":"0","summary":"Comfort Systems' profit margins have rarely been this good, but they could come under pressure due to import tariffs.Shares of Comfort Systems USA  slid 16.8% in February, according to data provided by S&P Global Market Intelligence. Part of this drop occurred after the company reported financial results for the fourth quarter of 2024 on Feb. 20, but the bigger drop happened earlier in the month and could be related to President Donald Trump's trade tariffs.The trade tariff situation is constantly changing, so my thoughts could quickly become outdated. But suffice it to say that Comfort Systems' costs could go up because of import tariffs -- the company specifically calls this out in the risk section of its financial filings. And if it can't raise prices by the same amount, its profit margins would go down, which is bad for the business and, consequently, for the stock.Before reporting Q4 results, Comfort Systems' stock was down about 10% during the month, and I'd wager that investors ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/03/07/why-comfort-systems-usa-stock-slid-17-last-month/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["LU0053671581.USD","LU0054578231.USD","BK4567","FIX","BK4129"],"gpt_icon":1},{"id":"2517304424","title":"BlackRock, Inc. (BLK): Jim Cramer Says, ‘It’s Worth Much More Than It’s Selling For!’","url":"https://stock-news.laohu8.com/highlight/detail?id=2517304424","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517304424?lang=en_us&edition=fundamental","pubTime":"2025-03-08 00:06","pubTimestamp":1741363586,"startTime":"0","endTime":"0","summary":"We recently published a list of Jim Cramer Looked At These 11 Stocks Recently. In this article, we are going to take a look at where BlackRock  stands against other stocks that Jim Cramer looked at recently.On Wednesday, Jim Cramer, the host of Mad Money, shared his thoughts on the volatile trading day, pointing out that President Donald Trump’s actions are reshaping how investors assess stocks. Cramer highlighted that before Trump came into the office, his method of evaluating a stock was looking at its price, earnings, revenues, and gross margins.“Now, though, I start with a simple question: Can President Trump hurt the stock? Can he damage it with an offhanded comment? Can he crush it in anger? And most important, does the price-to-earnings multiple make sense in this new world in light of the president’s love of tariffs and total hostility to the way this country’s been running the past, not to mention many of our country’s friends?”READ ALSO:10 Stocks on Jim Cramer’s RadarandJim C","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/blackrock-inc-blk-jim-cramer-160626994.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0130102774.USD","BK4135","LU1509826696.USD","LU1670628061.USD","LU2430703095.HKD","BK4534","LU0070302665.USD","BK4535","LU0980610538.SGD","LU2264538146.SGD","BK4585","LU1988902786.USD","LU2430703251.USD","IE00B64PRP62.GBP","LU1989771016.USD","IE00B3PB1722.GBP","LU1074936037.SGD","LU1291159041.SGD","LU1201861249.SGD","BLK","BK4533","LU0731783048.USD","IE00BVYPNV92.GBP","LU1064131342.USD","BK4581","LU0772969993.USD","BK4567","LU2592432038.USD","LU0320765489.SGD","LU0731783394.SGD","IE00BVYPNW00.USD","LU0640476718.USD","IE00BGHQF631.EUR","LU1670627923.USD","IE00B42XCP33.USD","LU1280957306.USD","IE00BDGV0183.EUR","LU2505996509.AUD","LU2430703178.SGD","LU0208291251.USD","LU1481011911.USD","BK4504","BK4588","LU0742537680.HKD","LU2505996681.GBP","LU1599440770.SGD","IE00BGHQF748.EUR","LU1481011671.HKD","LU0648001328.SGD","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2517437347","title":"Vertex Pharmaceuticals Gets UK Regulatory Approval for Alyftrek to Treat Cystic Fibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2517437347","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517437347?lang=en_us&edition=fundamental","pubTime":"2025-03-07 23:50","pubTimestamp":1741362611,"startTime":"0","endTime":"0","summary":"Vertex Pharmaceuticals  said Friday it received approval from the UK's Medicines and Healthcare products Regulatory Agency for Alyftrek to treat cystic fibrosis in patients six years and older with at least one F508del or another responsive mutation in the cystic fibrosis transmembrane conductance regulator gene.Alyftrek is a triple combination cystic fibrosis transmembrane conductance regulator modulator treatment, the company added.The US Food and Drug Administration approved Alyftrek in December 2024.Price: 488.10, Change: +2.38, Percent Change: +0.49","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["VRTX","LU2237438978.USD","IE00BFTCPJ56.SGD","BK4139","LU1585245621.USD","LU0058720904.USD","IE00B19Z9P08.USD","IE0002141913.USD","LU2362541273.HKD","LU2456880835.USD","LU0823416689.USD","LU1093756325.SGD","LU2362541513.USD","IE00BJJMRZ35.SGD","BK4567","LU0289739699.SGD","LU0889565916.HKD","IE00B19Z9Z06.USD","LU1069344957.HKD","IE00B2B36J28.USD","IE0002270589.USD","LU1035775433.USD","LU0417517546.SGD","LU0061475181.USD","IE00BZ9MQY76.HKD","IE0009355771.USD","BK4533","LU0256863811.USD","IE00B19Z3581.USD","LU2462157665.USD","BK4532","IE00B19Z3B42.SGD","LU0234570918.USD","LU0079474960.USD","LU0320765992.SGD","LU1093756168.USD","LU0109394709.USD","BK4585","LU2236285917.USD","IE00B4R5TH58.HKD","LU2324357040.USD","LU2362540622.SGD","IE00B894F039.SGD","LU2417539215.USD","LU1430594728.SGD","VERX","BK4588","IE00BJT1NW94.SGD"],"gpt_icon":0},{"id":"2517243241","title":"FactSet Research Is Maintained at Equal-Weight by Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2517243241","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517243241?lang=en_us&edition=fundamental","pubTime":"2025-03-07 23:30","pubTimestamp":1741361400,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/FDS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 07, 2025 10:30 ET (15:30 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0070302665.USD","LU0128525689.USD","LU0175139822.USD","BK4567","LU0052756011.USD","LU1267930227.SGD","FDS","LU2236285917.USD","LU0648001328.SGD","LU0708994859.HKD","BK4207","LU0211327993.USD","LU0256863811.USD","LU0106831901.USD","LU0742534661.SGD","LU0211328371.USD","LU1035773651.USD","LU0130102774.USD","LU0320765489.SGD","LU0267386448.USD","LU0208291251.USD","LU0072461881.USD","LU1668664300.SGD","IE0002270589.USD","LU0128525929.USD","LU0310799852.SGD","LU1506573853.SGD","LU2210149790.SGD","LU2210150020.SGD","LU0640476718.USD","LU0149725797.USD","LU0310800379.SGD","LU0310800965.SGD","LU1267930490.SGD","LU2461242641.AUD","LU0289960550.SGD","LU0683600562.USD","LU1069347547.HKD","LU0971096721.USD","LU1074936037.SGD","LU1201861249.SGD","LU1280957306.USD","LU2361044949.HKD","LU0130517989.USD","LU2095319765.USD","BK4559","LU0048573561.USD","LU2361044865.SGD","BK4588","LU2361045086.USD"],"gpt_icon":0},{"id":"2517434837","title":"BUZZ-Deutsche Bank initiates coverage on some US trucking firms","url":"https://stock-news.laohu8.com/highlight/detail?id=2517434837","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517434837?lang=en_us&edition=fundamental","pubTime":"2025-03-07 23:06","pubTimestamp":1741360009,"startTime":"0","endTime":"0","summary":"BUZZ-Deutsche Bank initiates coverage on some US trucking firms** Deutsche Bank initiates coverage on some U.S. trucking firms, including CH Robinson CHRW.O and Old Dominion ODFL.O, with \"buy\" rating ** Says ODFL's financial position will strengthen in the next up-cycle, \"as the co benefits from better fixed-cost absorption\"; PT at $236** Sets PT of $129 on CHRW, a 31% upside to stock's last close** Also starts J B Hunt JBHT.O with \"hold\" rating; PT at $167, a 3% upside to stock's last close** Rates for cross-border trucking to and from the U.S. jumped amid new tariffs on Canada and Mexico, as cos scrambled to accelerate shipments ahead of an expected increase in costs** YTD, S&P 500 Transportation Index .SPLRCTRN down 1.4%   ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250307:nL3N3PQ1B6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CHRW","LU0985489474.SGD","BK4504","BK4567","JBHT","LU0068578508.USD","BK4232","BK4533","BK4597","LU1303367103.USD","BK4588","BK4131","BK4520","LU0433182093.SGD","LU0878866978.SGD","IE0008368304.USD","LU2098885051.SGD","ARBU","ODFL","BK4022","LU1571399168.USD","BK4585","LU1489326972.SGD","BK4566"],"gpt_icon":0},{"id":"2517293434","title":"Vertex Pharmaceuticals announces MHRA approval of ALYFTREK for CF","url":"https://stock-news.laohu8.com/highlight/detail?id=2517293434","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517293434?lang=en_us&edition=fundamental","pubTime":"2025-03-07 23:05","pubTimestamp":1741359934,"startTime":"0","endTime":"0","summary":"Vertex announced that the United Kingdom Medicines and Healthcare products Regulatory Agency has granted approval for ALYFTREK, a once-daily next-i...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vertex-pharmaceuticals-announces-mhra-approval-of-alyftrek-for-cf?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vertex-pharmaceuticals-announces-mhra-approval-of-alyftrek-for-cf?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0002141913.USD","LU1815336091.USD","LU1093756325.SGD","BK4139","IE00B2B36J28.USD","LU0109394709.USD","BK4533","IE00B19Z3581.USD","IE00B894F039.SGD","LU1585245621.USD","LU2462157665.USD","LU0234570918.USD","LU0823416689.USD","LU2362540622.SGD","VERX","LU2362541273.HKD","LU2417539215.USD","BK4567","LU1559883803.SGD","VRTX","LU2324357040.USD","BK4093","IE0002270589.USD","IE00B19Z3B42.SGD","BK4585","LU2362541513.USD","LU0566484027.USD","LU2456880835.USD","LU0256863811.USD","IE00B19Z9P08.USD","IE00B4R5TH58.HKD","CF","IE00B19Z9Z06.USD","IE0009355771.USD","LU0320765992.SGD","LU0757428866.USD","LU1430594728.SGD","LU2237438978.USD","BK4532","IE00BZ9MQY76.HKD","BK4023","IE00BFTCPJ56.SGD","LU1069344957.HKD","LU0061475181.USD","LU0289739699.SGD","LU2236285917.USD","BK4588","LU0889565916.HKD","IE00BJJMRZ35.SGD","LU0079474960.USD"],"gpt_icon":0},{"id":"2517431273","title":"Vertex Pharmaceuticals Inc - Working With Nice and Nhs for Alyftrek Access","url":"https://stock-news.laohu8.com/highlight/detail?id=2517431273","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517431273?lang=en_us&edition=fundamental","pubTime":"2025-03-07 23:02","pubTimestamp":1741359720,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250307:nTUA7VCKSK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4567","LU0889565916.HKD","IE00BJJMRZ35.SGD","BK4139","LU0320765992.SGD","LU2362540622.SGD","BK4533","LU0058720904.USD","IE00B19Z9P08.USD","LU1093756168.USD","LU2462157665.USD","LU0417517546.SGD","BK4585","LU2236285917.USD","IE00BZ9MQY76.HKD","IE00B19Z3B42.SGD","LU2362541273.HKD","VRTX","IE0002270589.USD","IE00B894F039.SGD","IE0002141913.USD","LU2324357040.USD","LU0289739699.SGD","IE00B2B36J28.USD","LU0061475181.USD","IE0009355771.USD","IE00B19Z3581.USD","IE00B19Z9Z06.USD","IE00BFTCPJ56.SGD","LU0256863811.USD","LU1093756325.SGD","LU2237438978.USD","LU1035775433.USD","LU2362541513.USD","IE00B4R5TH58.HKD","LU2417539215.USD","LU1430594728.SGD","LU1585245621.USD","LU0079474960.USD","LU2456880835.USD","LU0823416689.USD","BK4532","LU1069344957.HKD","IE00BJT1NW94.SGD","LU0234570918.USD","BK4588","LU0109394709.USD"],"gpt_icon":0},{"id":"2517312774","title":"Vertex Announces UK Mhra Approval of Alyftrek® (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class Cftr Modulator for the Treatment of Cystic Fibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2517312774","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517312774?lang=en_us&edition=fundamental","pubTime":"2025-03-07 23:02","pubTimestamp":1741359720,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250307:nTUA7VCKSK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BJJMRZ35.SGD","BK4585","IE00B19Z3581.USD","LU0256863811.USD","LU0234570918.USD","LU0889565916.HKD","BK4533","LU2362541273.HKD","LU2462157665.USD","LU2236285917.USD","LU0320765992.SGD","IE00B2B36J28.USD","LU0058720904.USD","IE0002141913.USD","IE00BZ9MQY76.HKD","IE00B4R5TH58.HKD","LU0061475181.USD","LU2417539215.USD","LU2362540622.SGD","LU0417517546.SGD","LU1035775433.USD","BK4588","IE00BJT1NW94.SGD","IE00B19Z9P08.USD","LU1093756168.USD","LU0823416689.USD","IE0002270589.USD","IE00BFTCPJ56.SGD","LU1069344957.HKD","LU2324357040.USD","LU2362541513.USD","BK4139","VRTX","BK4532","IE00B19Z9Z06.USD","LU0109394709.USD","LU2237438978.USD","LU1430594728.SGD","LU1093756325.SGD","IE0009355771.USD","IE00B19Z3B42.SGD","IE00B894F039.SGD","LU2456880835.USD","BK4567","LU1585245621.USD","LU0079474960.USD","LU0289739699.SGD"],"gpt_icon":0},{"id":"2517439235","title":"Do Its Financials Have Any Role To Play In Driving Fastenal Company's (NASDAQ:FAST) Stock Up Recently?","url":"https://stock-news.laohu8.com/highlight/detail?id=2517439235","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517439235?lang=en_us&edition=fundamental","pubTime":"2025-03-07 22:00","pubTimestamp":1741356009,"startTime":"0","endTime":"0","summary":"Fastenal's  stock is up by a considerable 5.9% over the past month. As most would know, fundamentals are what usually guide market price movements over the long-term, so we decided to look at the company's key financial indicators today to determine if they have any role to play in the recent price movement. In this article, we decided to focus on Fastenal's  ROE.Return on Equity or ROE is a test of how effectively a company is growing its value and managing investors’ money. In other words, it is a profitability ratio which measures the rate of return on the capital provided by the company's shareholders.Return on Equity = Net Profit  ÷ Shareholders' Equity. So, based on the above formula, the ROE for Fastenal is:. While Fastenal has a three-year median payout ratio of 68% , the company has still seen a fair bit of ear","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/financials-role-play-driving-fastenal-140009184.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":[".IXIC","LU2210150020.SGD","PSQ","LU2210149790.SGD","USAW.SI","USJW.SI","BK4104","IE00BFXG0V08.USD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","LU2095319765.USD","BK4567","QLD","IE00BKPKM429.USD","TQQQ","MNQmain","IE00B5TLWC47.USD","SQQQ","NVIW.SI","TSYW.SI","NDAQ","BK4112","NQmain","QID","IE00BYQQ9H92.USD","BK4585","BK4588","IE00B3QW5Z07.USD","FAST"],"gpt_icon":1},{"id":"2517351644","title":"THE MEXICO FUND, INC. DECLARES DISTRIBUTION","url":"https://stock-news.laohu8.com/highlight/detail?id=2517351644","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517351644?lang=en_us&edition=fundamental","pubTime":"2025-03-07 22:00","pubTimestamp":1741356000,"startTime":"0","endTime":"0","summary":"COLUMBIA, Md., March 7, 2025 /PRNewswire/ -- The Mexico Fund, Inc. , announced that the Board of Directors  declared a distribution of $0.22 per share to stockholders of record on April 22, 2025, which is payable in cash on April 30, 2025.The Board has approved the continuation of the Fund's MDP during 2025. The Board may amend or terminate the MDP at any time without prior notice to stockholders. Since the implementation of the MDP in September 2008, the Fund has paid a total of $27.26 per share in cash distributions to stockholders.The amount of distributable income for each fiscal period depends on the aggregate gains and losses realized by the Fund during the entire year. Distributions may consist of net investment income, capital gains and return of capital, but the character of these distributions cannot be determined until after the end of the Fund's fiscal year. However, under the Investment Company Act of 1940, the Fund is required to indicate the source of each distribution t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/mexico-fund-inc-declares-distribution-140000450.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mexico-fund-inc-declares-distribution-140000450.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2092937221.SGD","MXF","LU1165135440.EUR","IE00BN0W2T93.GBP","BK4567","BK4588","LU1721428933.USD","IE00BN0W2V16.EUR","BK4121","LU0347712357.USD","BK4585","LU1543694498.USD","INC","LU2041044095.USD","LU2413666426.HKD","LU2413666699.HKD","A","IE00BN0W2W23.USD","FUND"],"gpt_icon":0},{"id":"2517455692","title":"COTY Stock Plunges More Than 25% in 3 Months: What Should You Do?","url":"https://stock-news.laohu8.com/highlight/detail?id=2517455692","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517455692?lang=en_us&edition=fundamental","pubTime":"2025-03-07 21:31","pubTimestamp":1741354260,"startTime":"0","endTime":"0","summary":"Coty Inc. COTY, a major player in the beauty industry, is grappling with rising costs and weaker-than-expected demand, especially in its key markets like China, Travel Retail Asia and the United States. During the second quarter of fiscal 2025, the company saw a decline in both top and bottom-line results and also missed the Zacks Consensus Estimate. Despite strong holiday sales in core markets, Coty couldn't capitalize on the momentum as retailers maintained tight inventory control, impacting sales growth.Such challenges have led to a notable 25.7% drop in its share price in the past three months. The stock underperformed the industry, the broader Zacks Consumer Staples sector and the S&P 500 in the said time frame. While the industry and the S&P 500 declined 21.4% and 3.3%, respectively, the sector rose 1.5%.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/coty-stock-plunges-more-25-133100767.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","LU0266013472.USD","NUS","IE00B19Z3581.USD","LFL","COTY","IE00B19Z3B42.SGD","BK4532","BK4585","LU0823411888.USD","ULTA","IE0002270589.USD","BK4200","BK4183","BK4567","BK4146","IE00B7SZLL34.SGD","DECK"],"gpt_icon":0},{"id":"2517437400","title":"Is the Options Market Predicting a Spike in Applied Materials (AMAT) Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2517437400","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517437400?lang=en_us&edition=fundamental","pubTime":"2025-03-07 21:30","pubTimestamp":1741354200,"startTime":"0","endTime":"0","summary":"Investors in Applied Materials, Inc. AMAT need to pay close attention to the stock based on moves in the options market lately. That is because the Mar 21, 2025 $90 Call had some of the highest implied volatility of all equity options today.Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.Clearly, options traders are pricing in a big move for Applied Materials shares, but what is the fundamental picture for the company?Applied Materials, Inc.  : Free Stock Analysis Report. This article originally published on Zacks Investment Research .","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/options-market-predicting-spike-applied-133000182.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4543","LU0444973449.USD","LU0354030438.USD","LU1815333072.USD","LU2089283258.USD","BK4588","SG9999001424.SGD","LU2023250504.SGD","LU2106854487.HKD","LU0792757196.USD","LU1815336760.USD","LU0158827948.USD","BK4533","LU0868494617.USD","LU1674673691.USD","LU2023250843.SGD","BK4516","LU0109392836.USD","LU1917777945.USD","IE00BQXX3C00.GBP","AMAT","LU0957791311.USD","LU1267930813.SGD","LU1989773731.SGD","LU1674673428.USD","BK4519","LU2111349929.HKD","LU0957808578.USD","LU1046421795.USD","LU1778281490.HKD","IE00B5949003.HKD","LU1989763005.USD","BK4534","LU0476273544.USD","LU1974910355.USD","BK4567","LU2089284900.SGD","LU2028103732.USD","LU1153585028.USD","LU0942090050.USD","LU2271345857.HKD","LU0061474960.USD","LU0354030511.USD","BK4585","SG9999002232.USD","BK4544","LU0348723411.USD","BK4518","LU2458330243.SGD","ARKG"],"gpt_icon":0},{"id":"2517362604","title":"Is it Worth Adding ResMed Stock to Your Portfolio Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2517362604","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517362604?lang=en_us&edition=fundamental","pubTime":"2025-03-07 21:11","pubTimestamp":1741353060,"startTime":"0","endTime":"0","summary":"ResMed Inc.’s RMD growth in the second quarter of fiscal 2025 can be attributed to the robust performance of its Mask business. Its Device sales continue to drive overall revenue growth. The company’s SaaS business growth is driven by strategic buyouts. However, the increasing debt burden on ResMed’s operations remains a concern.In the past year, shares of this Zacks Rank #2  company have surged 16.9%, outperforming the industry’s 9.2% growth and the S&P 500 composite’s 14.5% rise.The renowned medical device company has a market capitalization of $32.87 billion. RMD has an earnings yield of 4.2%, outpacing the industry’s 1.5%. The company’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 6.86%.Robust Mask Sales: ResMed continues to see strong demand for its market-leading mask portfolio, gaining from a competitor’s recall. Continued product development is driving growth within this business globally. The company has successfully int","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/worth-adding-resmed-stock-portfolio-131100726.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0238689110.USD","LU1880398471.USD","LU1983299246.USD","LU2362541513.USD","LU0266013472.USD","LU0528227936.USD","LU2491049909.HKD","BSX","LU0011850046.USD","LU0128525689.USD","LU1718418525.SGD","LU2491050154.USD","LU2265009873.SGD","RMD.AU","LU2362540622.SGD","LU0889566641.SGD","BK4548","LU0077335932.USD","LU0048584097.USD","LU0162691827.USD","LU2324357040.USD","LU1791710400.SGD","BK4567","LU0114720955.EUR","LU2506951875.HKD","LU0211327993.USD","LU0072461881.USD","IE0002141913.USD","LU0122379950.USD","BK4082","LU2244417387.USD","RMD","LU0792757196.USD","LU0823416689.USD","LU1804176565.USD","LU0310800965.SGD","LU2506952170.USD","CAH","BK4504","LU2506951958.HKD","IE00BFTCPJ56.SGD","LU1023059063.AUD","LU0823417737.USD","LU1571399168.USD","LU2362541273.HKD","IE0009355771.USD","LU2087625088.SGD","LU2177674079.SGD","BK4175","SG9999001440.SGD","PAHC"],"gpt_icon":0},{"id":"2517480505","title":"InflaRx Showcases Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2517480505","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517480505?lang=en_us&edition=fundamental","pubTime":"2025-03-07 21:00","pubTimestamp":1741352400,"startTime":"0","endTime":"0","summary":"JENA, Germany, March  07, 2025  (GLOBE NEWSWIRE) -- InflaRxN.V.(Nasdaq:IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/07/3038913/0/en/InflaRx-Showcases-Vilobelimab-s-Role-in-Immuno-Dermatology-at-the-2025-AAD-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BBT3K403.USD","BK4534","SG9999014542.SGD","LU1162221912.USD","LU1868836914.USD","SG9999014567.USD","LU0689626769.HKD","BK4139","IE00BWXC8680.SGD","PD","LU1066053197.SGD","LU1430594728.SGD","LU0234572021.USD","SG9999015358.SGD","IE00B3T34201.USD","USA","PG","BK4559","SG9999002232.USD","LU1868837136.USD","LU2129689431.USD","BK4535","LU2129689514.USD","LU0061475181.USD","LU1929549753.HKD","SG9999014575.USD","LU0094547139.USD","BNTX","BK4568","IE00BLSP4239.USD","BK4504","LU1169589451.USD","PK","SG9999002224.SGD","BK4018","LU1868837300.USD","ARDS","LU1585245621.USD","SG9999015341.SGD","BK4567","LU0868494617.USD","LU2552382215.SGD","LU1066051498.USD","BK4533","LU1868836591.USD","SG9999001440.SGD","BK4581","LU0234570918.USD","BK4558","BK4181"],"gpt_icon":0},{"id":"2517448228","title":"Vertex Pharmaceuticals' Triple Combination Cystic Fibrosis Therapy Alyftrek Receives Approval in UK","url":"https://stock-news.laohu8.com/highlight/detail?id=2517448228","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517448228?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:46","pubTimestamp":1741351613,"startTime":"0","endTime":"0","summary":"Vertex Pharmaceuticals' (VRTX) triple combination medicine deutivacaftor, tezacaftor,vanzacaftor was approved by the UK's Medicines and Healthcare products Regulatory Agency for treating cystic fibros","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0823416689.USD","IE00B19Z3581.USD","LU0234570918.USD","LU1585245621.USD","LU2417539215.USD","LU2362540622.SGD","LU1093756325.SGD","IE00BJT1NW94.SGD","LU0256863811.USD","LU0289739699.SGD","IE0002141913.USD","LU2362541273.HKD","LU2462157665.USD","BK4567","LU1430594728.SGD","VERX","LU0058720904.USD","BK4533","LU2324357040.USD","IE00BFTCPJ56.SGD","IE0002270589.USD","IE00BZ9MQY76.HKD","IE00BJJMRZ35.SGD","LU1093756168.USD","BK4139","LU2236285917.USD","IE00B19Z9Z06.USD","BK4588","LU0320765992.SGD","IE0009355771.USD","IE00B2B36J28.USD","VRTX","LU1069344957.HKD","LU0061475181.USD","LU2362541513.USD","LU2237438978.USD","BK4585","IE00B894F039.SGD","BK4532","IE00B19Z3B42.SGD","LU2456880835.USD","LU0417517546.SGD","IE00B4R5TH58.HKD","LU1035775433.USD","LU0079474960.USD","LU0889565916.HKD","IE00B19Z9P08.USD","LU0109394709.USD"],"gpt_icon":0}],"pageSize":16,"totalPage":40,"pageCount":30,"totalSize":640}]}}